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risk group, ﬁnally became a high risk patient. There was a change in PTV and RT dose in 19.2% of patients. Based in MRI ﬁndings,
we changed the decision of treating with HT in 11.5% of patients. Postoperative RT: 33.3% pelvic relapses were diagnosed with
MRI, which inﬂuenced the decision of treatment. In summary, MRI signiﬁcantly inﬂuenced our clinical practice, changing our
treatment in 31.7% of patients.
Conclusion. 3T functional MRI provides an optimal staging for prostate cancer. Its routine use might represent signiﬁcant changes
in the management of such patients.
http://dx.doi.org/10.1016/j.rpor.2013.03.807
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Purpose/objectives. Higher radiation dose levels have been shown to be associated with improved tumor-control outcomes in
localized PCa pts. We previously (SEOR, 2007) presented our preliminary results of escalating doses with 3Dc-EBRT in localized
PCa pts. The aim of this study is to updated long-term results and to identify predictors of biochemical, local control, survival
and toxicity outcomes for pts with clinically localized PCa treated with escalating 3Dc-EBRT.
Methods/materials. From 2003 to 2005 a total of 339 pts diagnosed with cT1–T4 localized PCa were analyzed. Prescription dose to
prostate was 72Gy for low, 74Gy and 6 months of androgen deprivation therapy (ADT) for intermediate, and 76Gy (46Gy to pelvis)
and 2-year of ADT for high-risk. Factors associated to biochemical, local control, survival and toxicity were analysed. Estimates
of survival were determined using Kaplan–Meier methods. Unadjusted and adjusted hazard ratios were calculated using the Cox
regression model.
Results. Mean age was 70 years (range 56–84 years). Pts were staged as low, 60 pts (18%), intermediate, 102 pts (30%) and high-risk
177 pts (52%). A total of 254 pts (75%) received ADT, and 149 pts (44%) received pelvic radiation. Mean rectal and bladder doses
were 49.8Gy and 44.6Gy, respectively. Rectal and bladder constraints (Vr50 and Vb50) were not met in 17% and 34%, respectively.
Biochemical failure (Phoenix deﬁnition) was observed in 7 pts (12%) for low, 10 pts (10%) for intermediate, and 30 pts (17%) for
high-risk. With a median follow-up of 7.28 years (range 1.4–15 years), the 10-year OS and BRFS was 79% and 80%, respectively.
The 10-year BRFS for low, intermediate and high-risk group was 77%, 87% and 76.5% (p>0.05). On multivariate analysis, initial
PSA 10–20ng/ml (p 0.003), Gleason score≥7 (p 0.001), and nadir PSA>0.5ng/ml post-RT (p 0.002) were strongly associated with
biochemical failure. Onmultivariate analysis, time to relapse<24months (p 0.001)were associatedwithworseOS.Onmultivariate
analysis, Gleason score 3+4/4+3 (p 0.003) and time to relapse<24 months (p 0.001) were associated with death due to PCa. There
were not observed any grade 4 or 5 rectal or bladder toxicities (CTCv3).
Conclusions. At 10-year, adapted dose escalation 74Gy and 76Gy 3Dc-EBRT were consistently associated with high biochemical
control and overall survival in intermediate and high-risk PCa pts. Higher Gleason score≥7, nadir psa>0.5ng/ml post-RT, time
to relapse<24 months are strong predictors of biochemical failure, worse OS and increased death due to PCa.
http://dx.doi.org/10.1016/j.rpor.2013.03.808
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Introduction. In prostate cancer (PC) higher biologically effective dose (BED) may be delivered with very conformal techniques like
combined treatment with external beam radiotherapy (EBRT) and boost with high-dose-rate brachytherapy (HDR-BT).
Objectives. Analysis of our ten years experience with EBRT combined with boost with HDR-BT in PC.
Materials and methods. Between June 2002 to December 2011, 648 patients with localized PC were treated using EBRT and boost
with HDR-BT. Median age 71 years. Classiﬁcation by risk groups: 21 (3.1%) low, 337 (52.1%) intermediate and 290 (44.8%) high risk.
All patients received EBRT to prostate and seminal vesicles (median dose of 57.68Gy) and boost with HDR-BT (median dose of
9.73Gy); 320 (49.4%) patients received elective pelvic radiotherapy. The median BED was 200.4Gy. The median values for prostate
volume was 27.32 cm3 and V100=93.3%. BT-planning was performed with tomography images in 347 (53.6%) and in real time
with ultrasound images (Swift) in 301 (46.4%) patients. Androgen blockade 80.9% of patients. We analyzed predictive factors
in relation with tumor (risk group, perineural invasion), implant (prostate volume, number of needles, V100) and treatment
(duration, sequences, BED and planning with tomography vs Swift).
Results. With a median follow up of 61.1 months, the 5 and 10 years actuarial rates of biochemical failure free survival (BFFS) and
disease free survival other than BFFS (DFS) were 86.6%/96.4% and 69.6%/72.6%. Rates of genitourinary acute and chronic toxicities
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grade 2 or greater were 6.8% and 8.1%; and for gastrointestinal toxicities were 2.7% and 2%. We have found only a statistically
signiﬁcant difference in univariate analysis in rate of DFS with Swift (1.7%) vs tomography (7%).
Conclusions. In patients with PC, the treatment with EBRT and boost with HDR-BT allows deliver high BED with excellent results
and minimal toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.809
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Objective. The International Diabetes Federation (IDF) estimated that around 20–25% of the adult population of the world has
metabolic syndrome (MetS). The patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT), have
been reported to have higher prevalence of MetS. The objective of the study was to assess, the prevalence of MetS in patients
with PC who have received or will receive radiation therapy (RT) with radical intention and ADT.
Materials and methods. Multicenter prospective observational cross-sectional study of patients with PC who have received or will
receive RT with radical intention and ADT (6, 12–18, ≥24 months, and a control group without ADT), with the main primary
objective to analyze the prevalence of MetS in these pts. The presence of MetS was deﬁned according to the updated National
Cholesterol Education Program’s Adult Treatment Panel III by the presence of 3 or more of the following risk factors: (1) waist
circumference≥102 cm (European Cardiovascular Societies), (2) fasting blood sugar≥100mg/dL or previously diagnosed type
2 diabetes, (3) serum triglyceride level≥150mg/dL or pharmacological treatment for it, (4) systolic blood pressure≥130mm
Hg or diastolic blood pressure≥85mm Hg or previously diagnosed hypertension, and (5) high-density lipoprotein (cHDL) choles-
terol < 40 mg/dL. The study was approved by the Clinical Research Ethics Committee and the patient signed the informed consent
form.
Results. From November 2011 to October 2012, 256 pts were included in the study (50 pts without ADT, 55 pts with 6 months of
hormonal therapy, 91 pts in the group of 12–18 months and 60 pts in the group of ≥24 months ADT), and according to the above
criteria, 118 pts (46%) had MetS and are the object of our study. Median age was 72 years old (range 56-86). The prevalence of
MetS was 19.5% in patients without ADT, 20.3% in patients that received ADT for 6 months, 35.6% in pts treated for 12–18 months
with ADT and 24.6% in pts that received >24 months of hormonal therapy. The majority of pts had no family history of diabetes
mellitus, hypertension or dislipidemia.
Conclusion. According to our results patients with prostate cancer treated with androgen deprivation therapy for 12–18 months
present a higher prevalence of metabolic syndrome than patients treated with shorter or longer periods of hormonal treatment
and the general population.
http://dx.doi.org/10.1016/j.rpor.2013.03.810
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Purpose/objectives. Ki67 is a proliferation marker that provides an accurate estimate of growth fraction and outcome for patients
with prostate cancer. Expression of ERG (androgen dependent due to TMPRSS2-ERG fusion), are present in more than 50% of
